Dianthus Therapeutics, Inc.
DNTH
$43.97
$1.694.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -126.35M | -114.75M | -100.73M | -84.97M | -67.09M |
| Total Depreciation and Amortization | 409.00K | 426.00K | 438.00K | 412.00K | 437.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.59M | 10.53M | 8.62M | 6.73M | 5.59M |
| Change in Net Operating Assets | 3.82M | 3.57M | 803.00K | -351.00K | -1.52M |
| Cash from Operations | -109.52M | -100.23M | -90.87M | -78.18M | -62.59M |
| Capital Expenditure | -106.00K | -126.00K | -97.00K | -105.00K | -84.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -183.04M | -241.11M | -266.41M | -286.71M | -271.86M |
| Cash from Investing | -183.15M | -241.24M | -266.51M | -286.81M | -271.94M |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | 0.00 |
| Issuance of Common Stock | 315.09M | 40.70M | 40.18M | 270.29M | 230.61M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -172.00K | 0.00 | -2.24M | -14.67M | -19.53M |
| Cash from Financing | 314.92M | 40.70M | 37.94M | 255.62M | 211.08M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 22.25M | -300.77M | -319.44M | -109.37M | -123.45M |